Drug Trial Radar · NCT00700310
Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Last checked: Nov 19, 2026Latest source record: Jan 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
712
Actual
Start
Aug 2008
Primary completion
Aug 2009
Study completion Jan 2010
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jun 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
Conditions
- Refractory Partial Seizures
Interventions
perampanelDrug
2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
perampanelDrug
4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
perampanelDrug
8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
PlaceboDrug
Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)Time frame: Baseline (Pre-randomization) through Week 19
Locations
137 sites in 23 countries. Site status is shown where the registry gives one.
Site not named
Clayton, Australia
Site not named
Fitzroy, Australia
Site not named
Parkville, Australia
Site not named
West Heidelberg, Australia
Site not named
Woodville, Australia
The Queen Elizabeth Hospital
Woodville, South Australia, Australia
Site not named
Woodville South, South Australia, Australia
Site not named
Clayton, Victoria, Australia
Site not named
Fitzroy, Victoria, Australia
Site not named
Heidelberg, Victoria, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Pleven, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Brno, Czechia
Site not named
Olomouc, Czechia
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Tallinn, Estonia
Site not named
Tallinn, Estonia
Site not named
Tartu, Estonia
Site not named
Düsseldorf, Germany
Site not named
Kehl-Kork, Germany
Site not named
Konigstein-Falkenstein, Germany
Site not named
Mainz, Germany
Site not named
Marburg, Germany
Site not named
München, Germany
Site not named
München, Germany
Site not named
Ulm, Germany
Site not named
Westerstede, Germany
Queen Mary Hospital
Hong Kong, Hong Kong
Site not named
Hong Kong, Hong Kong
Queen Elizabeth Hospital
Kowloon, Hong Kong
United Christian Hospital
Kowloon, Hong Kong
Site not named
Kowloon, Hong Kong
Prince of Wales Hospital
Shatin, Hong Kong
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.